Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Nov 8;9(4):199-207.
doi: 10.1038/nrclinonc.2011.165.

Adaptive clinical trials in oncology

Affiliations
Review

Adaptive clinical trials in oncology

Donald A Berry. Nat Rev Clin Oncol. .

Abstract

Modern oncology drug development faces challenges very different from those of the past and it must adapt accordingly. The size and expense of phase III clinical trials continue to increase, but the success rate remains unacceptably low. Adaptive trial designs can make development more informative, addressing whether a drug is safe and effective while showing how it should be delivered and to whom. An adaptive design is one in which the accumulating data are used to modify the trial's course. Adaptive designs are ideal for addressing many questions at once. For example, a single trial might identify the appropriate patient population, dose and regimen, and therapeutic combinations, and then switch seamlessly into a phase III confirmatory trial. Adaptive designs rely on information, including from patients who have not achieved the trial's primary end point. Longitudinal models of biomarkers (including tumor burden assessed via imaging) enable predictions of primary end points. Taking a Bayesian perspective facilitates building an efficient and accurate trial, including using longitudinal information. A wholly new paradigm for drug development exemplifying personalized medicine is evinced by an adaptive trial called I-SPY2, in which drugs from many companies are evaluated in the same trial--a phase II screening process.

PubMed Disclaimer

References

    1. Clin Pharmacol Ther. 2009 Jul;86(1):97-100 - PubMed
    1. J Natl Cancer Inst. 2009 Dec 2;101(23):1642-9 - PubMed
    1. Clin Trials. 2005;2(4):295-300; discussion 301-4, 364-78 - PubMed
    1. N Engl J Med. 2011 Mar 17;364(11):985-7 - PubMed
    1. J Clin Oncol. 2007 Nov 20;25(33):5218-24 - PubMed

MeSH terms